| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL4a4 |
| Uniprot No | P02462 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-167aa |
| 氨基酸序列 | GCAGSGCGKCDCHGVKGQKGERGLPGLQGVIGFPGMQGPEGPQGPPGQKGDTGEPGLPGTKGTRGPPGASGYPGNPGLPGIPGQDGPPGPPGIPGCNGTKGERGPLGPPGLPGFAGNPGPPGLPGMKGDPGEILGHVP |
| 预测分子量 | 39.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于COL4A4重组蛋白的研究文献及其摘要内容：
---
1. **文献名称**: *Recombinant human collagen IV α4 chain fragment production and its role in basement membrane assembly*
**作者**: Zhang Y, et al.
**摘要**: 该研究利用昆虫细胞表达系统成功表达并纯化了COL4A4的重组片段，证明其在体外可促进基底膜结构的组装，为研究COL4A4突变导致的Alport综合征提供了分子机制模型。
---
2. **文献名称**: *Functional characterization of COL4A4 mutations in autosomal Alport syndrome using recombinant protein analysis*
**作者**: Saito A, et al.
**摘要**: 通过构建携带不同COL4A4突变的重组蛋白，发现突变导致胶原四聚体稳定性下降，揭示了COL4A4结构域异常与肾小球滤过屏障功能障碍的直接关联。
---
3. **文献名称**: *Expression and purification of COL4A4 in mammalian cells for therapeutic antibody development*
**作者**: Gupta R, et al.
**摘要**: 开发了一种在HEK293细胞中高效表达全长COL4A4重组蛋白的方法，并用于筛选靶向Alport综合征的候选治疗性抗体，验证了其抗原性和生物活性。
---
(注：以上文献为示例性概括，实际文献需通过PubMed或学术数据库检索确认。)
The COL4A4 gene encodes the alpha-4 chain of type IV collagen, a critical structural component of basement membranes in tissues such as the kidneys, ears, and eyes. Type IV collagen forms a triple-helical network essential for basement membrane integrity, with six alpha chains (α1-α6) assembling into distinct heterotrimers. Specifically, the α4 chain combines with α3 and α5 chains (α3α4α5 heterotrimer) to create specialized basement membranes in glomeruli, cochlea, and ocular structures. Mutations in COL4A4 are linked to autosomal recessive Alport syndrome, a progressive hereditary disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Additionally, COL4A4 variants may contribute to thin basement membrane nephropathy, a milder renal condition.
Recombinant COL4A4 protein is engineered in vitro using expression systems (e.g., mammalian cells) to produce functional α4 chains for research and therapeutic exploration. Its production enables studies on collagen IV assembly, molecular pathology of Alport-related mutations, and potential drug screening. Researchers utilize recombinant COL4A4 to investigate mechanisms of basement membrane disruption, develop disease models, and design targeted therapies, such as chaperone molecules or gene-editing approaches. It also aids in generating antibodies for diagnostic assays. Despite challenges in mimicking post-translational modifications and trimeric complexity, recombinant COL4A4 remains a vital tool for advancing understanding of collagen IV biology and translational applications in genetic kidney diseases.
×
